b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31165204</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>05</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>05</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1432-0851</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>68</Volume>\n                    <Issue>7</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Jul</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Cancer immunology, immunotherapy : CII</Title>\n                <ISOAbbreviation>Cancer Immunol. Immunother.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>PLAC1: biology and potential application in cancer immunotherapy.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1039-1058</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-019-02350-8</ELocationID>\n            <Abstract>\n                <AbstractText>The emergence of immunotherapy has revolutionized medical oncology with unprecedented advances in cancer treatment over the past two decades. However, a major obstacle in cancer immunotherapy is identifying appropriate tumor-specific antigens to make targeted therapy achievable with fewer normal cells being impaired. The similarity between placentation and tumor development and growth has inspired many investigators to discover antigens for effective immunotherapy of cancers. Placenta-specific 1 (PLAC1) is one of the recently discovered placental antigens with limited normal tissue expression and fundamental roles in placental function and development. There is a growing body of evidence showing that PLAC1 is frequently activated in a wide variety of cancer types and promotes cancer progression. Based on the restricted expression of PLAC1 in testis, placenta and a wide variety of cancers, we have designated this molecule with new terminology, cancer-testis-placenta (CTP) antigen, a feature that PLAC1 shares with many other cancer testis antigens. Recent reports from our lab provide compelling evidence on the preferential expression of PLAC1 in prostate cancer and its potential utility in prostate cancer immunotherapy. PLAC1 may be regarded as a potential CTP antigen for targeted cancer immunotherapy based on the available data on its promoting function in cancer development and also its expression in cancers of different histological origin. In this review, we will summarize current data on PLAC1 with emphasis on its association with cancer development and immunotherapy.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Mahmoudian</LastName>\n                    <ForeName>Jafar</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ghods</LastName>\n                    <ForeName>Roya</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nazari</LastName>\n                    <ForeName>Mahboobeh</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jeddi-Tehrani</LastName>\n                    <ForeName>Mahmood</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ghahremani</LastName>\n                    <ForeName>Mohammad Hossein</ForeName>\n                    <Initials>MH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Pharmacology Building, Enghelab St., Tehran, 1417614411, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ghaffari-Tabrizi-Wizsy</LastName>\n                    <ForeName>Nassim</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>SFL Chicken CAM Lab, Institute of Pathophysiology and Immunology, Medical University of Graz, 8010, Graz, Austria.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ostad</LastName>\n                    <ForeName>Seyed Nasser</ForeName>\n                    <Initials>SN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran. ostadnas@tums.ac.ir.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Pharmacology Building, Enghelab St., Tehran, 1417614411, Iran. ostadnas@tums.ac.ir.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zarnani</LastName>\n                    <ForeName>Amir-Hassan</ForeName>\n                    <Initials>AH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Nafisi Building, Enghelab St., Tehran, 1417613151, Iran. zarnania@tums.ac.ir.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran. zarnania@tums.ac.ir.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran. zarnania@tums.ac.ir.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>94-01-57-27939</GrantID>\n                    <Agency>Tehran University of Medical Sciences</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>960511-036</GrantID>\n                    <Agency>Avicenna Research Institute</Agency>\n                    <Country/>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>06</Month>\n                <Day>05</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Germany</Country>\n            <MedlineTA>Cancer Immunol Immunother</MedlineTA>\n            <NlmUniqueID>8605732</NlmUniqueID>\n            <ISSNLinking>0340-7004</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C415583">PLAC1 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011257">Pregnancy Proteins</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>\n                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010920" MajorTopicYN="N">Placenta</DescriptorName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011257" MajorTopicYN="N">Pregnancy Proteins</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013737" MajorTopicYN="N">Testis</DescriptorName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Cancer</Keyword>\n            <Keyword MajorTopicYN="N">Development</Keyword>\n            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>\n            <Keyword MajorTopicYN="N">PLAC1</Keyword>\n            <Keyword MajorTopicYN="N">Placenta</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>08</Month>\n                <Day>22</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>05</Month>\n                <Day>24</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>6</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>6</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>6</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31165204</ArticleId>\n            <ArticleId IdType="doi">10.1007/s00262-019-02350-8</ArticleId>\n            <ArticleId IdType="pii">10.1007/s00262-019-02350-8</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'